Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday, Wall Street Zen reports.
Several other equities analysts also recently issued reports on GLSI. HC Wainwright boosted their price objective on Greenwich LifeSciences from $69.00 to $70.00 and gave the stock a "buy" rating in a research report on Wednesday. Weiss Ratings upgraded shares of Greenwich LifeSciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $70.00.
View Our Latest Report on Greenwich LifeSciences
Greenwich LifeSciences Stock Performance
NASDAQ:GLSI opened at $19.48 on Friday. Greenwich LifeSciences has a one year low of $7.78 and a one year high of $34.10. The business's 50-day simple moving average is $16.87 and its 200 day simple moving average is $20.77. The stock has a market cap of $285.95 million, a price-to-earnings ratio of 0.00 and a beta of 1.57.
Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.06). On average, equities research analysts predict that Greenwich LifeSciences will post -1.48 EPS for the current year.
Institutional Trading of Greenwich LifeSciences
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Ancora Advisors LLC grew its position in Greenwich LifeSciences by 101.2% in the third quarter. Ancora Advisors LLC now owns 21,610 shares of the company's stock worth $390,000 after buying an additional 10,870 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Greenwich LifeSciences by 44.4% during the 3rd quarter. Goldman Sachs Group Inc. now owns 56,793 shares of the company's stock valued at $1,025,000 after acquiring an additional 17,464 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Greenwich LifeSciences during the 2nd quarter worth $11,398,000. Deutsche Bank AG bought a new stake in shares of Greenwich LifeSciences during the 2nd quarter worth $126,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Greenwich LifeSciences in the 2nd quarter worth $1,124,000. 4.16% of the stock is currently owned by institutional investors.
Key Headlines Impacting Greenwich LifeSciences
These are some of the GLSI headlines that stood out recently:
About Greenwich LifeSciences
(
Get Free Report)
Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to reduce the risk of breast cancer recurrence. The company's work centers on GP2, an investigational peptide-based vaccine designed for patients with HER2/neu-positive breast cancer who have completed standard treatment. GP2 is intended to stimulate an immune response against cancer cells expressing HER2/neu and is administered with the immune-system stimulant GM-CSF. Greenwich LifeSciences is evaluating the candidate in clinical trials; it does not have an approved commercial product.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Greenwich LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.
While Greenwich LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.